Myofascial Pain Syndrome Epidemiology Forecast 2025-2034

Myofascial pain is a common cause of both acute and chronic pain. Myofascial pain syndrome epidemiology forecast indicates that the exact prevalence is challenging to determine because there are no clear diagnostic criteria. It is estimated that 20% to 95% of patients presenting with musculoskeletal pain to general medicine or pain management clinics are diagnosed with myofascial pain, according to a research article published in the Best Practice & Research Clinical Rheumatology (2024). Myofascial pain syndrome most commonly affects people aged 27 to 50 and is often linked to conditions like chronic tension headaches, jaw pain, and post-whiplash syndrome.

Myofascial Pain Syndrome Epidemiology Forecast Report Coverage

The “Myofascial Pain Syndrome Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of myofascial pain syndrome. It projects the future incidence and prevalence rates of myofascial pain syndrome cases across various populations. The study covers age and type as major determinants of the myofascial pain syndrome population. The report highlights patterns in the prevalence of myofascial pain syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on myofascial pain syndrome epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Myofascial Pain Syndrome Understanding: Disease Overview

Myofascial pain syndrome (MPS) refers to a nonarticular musculoskeletal pain disorder, which is characterized by the presence of myofascial trigger points. It is often linked to muscle overuse, injury, poor posture, or prolonged stress. Trigger points or tight, painful areas within muscles may arise from repetitive strain, trauma, or nerve irritation. Stress and tension in daily life are also contributing factors. The primary symptom of myofascial pain syndrome is pain in the muscle, either in one spot or spreading to other areas. Other common symptoms include muscle tightness, tenderness, and weakness, among others. The diagnosis is typically based on physical examination and patient history.

Myofascial Pain Syndrome Epidemiology Perspective

The myofascial pain syndrome epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for myofascial pain syndrome epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The myofascial pain syndrome detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• As per a research article published in the Best Practice & Research Clinical Rheumatology (2024), about 20% to 95% of patients presenting with musculoskeletal pain to general medicine or pain management clinics are estimated to be diagnosed with myofascial pain.
• The Cleveland Clinic reports that myofascial pain syndrome is common, with experts estimating that approximately 85% of the general population will experience the condition at some point in their lives.
• Research indicates that between 30% and 93% of individuals with widespread pain also have myofascial trigger points (MTrPs). Additionally, studies have found that 63.5% to 90% of people with low back pain experience myofascial pain syndrome.
• According to a cross-sectional study published in Knee (2019), myofascial pain syndrome linked with knee osteoarthritis did not appear to be influenced by factors like sex or age.
• Urits, Ivan, et al. (2020) suggest that myofascial pain is the leading cause of pain, accounting for 85% of back pain and 54.6% of chronic head and neck pain.

Country-wise Myofascial Pain Syndrome Epidemiology Segment

The myofascial pain syndrome epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of myofascial pain syndrome varies significantly between countries due to differences in factors such as healthcare access, diagnostic practices, lifestyle patterns, and the prevalence of risk factors like stress, physical inactivity, and occupational hazards. In the United States, about 14.4% of the general population experiences chronic musculoskeletal pain. Around 21% to 93% of people with regional pain complaints or pain in specific areas of the body have myofascial pain. Studies show that 25% to 54% of people without any symptoms have trigger points in their muscles that are inactive or latent.

Myofascial Pain Syndrome: Treatment Overview

The treatment approach for myofascial pain syndrome focuses on relieving pain, reducing muscle tension, and improving the function of affected muscles. Physical therapy, massage therapy, and dry needling are some of the common treatment options.

Myofascial pain syndrome therapeutics include nonsteroidal anti-inflammatory drugs (NSAIDs) or muscle relaxants that are prescribed to reduce pain and inflammation. Antidepressants are recommended in cases where chronic pain is also linked to mood disorders or sleep disturbances. Recent advancements in myofascial pain syndrome treatment include the use of platelet-rich plasma (PRP) therapy and shockwave therapy.

Key Questions Answered

• What are the key findings of myofascial pain syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with myofascial pain syndrome across the 8 major markets during the forecast period?
• What was the country-wise myofascial pain syndrome epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of myofascial pain syndrome patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of myofascial pain syndrome during the forecast period of 2025-2034?
• What are the currently available treatments in the myofascial pain syndrome market?
• What are the disease risks, signs, symptoms, and unmet needs of myofascial pain syndrome?

Scope of the Myofascial Pain Syndrome Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of myofascial pain syndrome based on several factors.
• The Myofascial Pain Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The myofascial pain syndrome report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.